Drug Profile

Selnoflast - Roche

Alternative Names: NLRP3i - Roche; RG 6418; RO-7486967; Somalix

Latest Information Update: 13 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Inflazome
Developer Roche
Class Anti-inflammatories; Antiasthmatics; Antiparkinsonians; Aromatic hydrocarbons; Piperidines; Small molecules; Urea compounds
Mechanism of Action NLRP3 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase I Asthma; Chronic obstructive pulmonary disease; Inflammation; Parkinson's disease; Ulcerative colitis

09 May 2024 Phase I development for Inflammation is ongoing in Ireland (Roche pipeline, May 2024)
10 Jul 2023 Phase-I clinical trials in Asthma in Netherlands, Germany, United Kingdom, Canada, Belgium (PO) (EudraCT2023-504304-29-00) (ISRCTN73873157)
28 Jun 2023 No recent reports of development identified for phase-I development in Inflammation in Ireland (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com